

A

JC491 U.S. PTO
12/03/97

Atty. Dkt. No.: 34477.2
USSN: Unassigned
Inventor: M. Michael Wolfe, *et al.*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

M. MICHAEL WOLFE, *et al.*

Entitled: *Specific Antagonists for Glucose-Dependent Insulinotropic Polypeptide (GIP)*

To the Assistant Commissioner
for Patents
Box Patent Application
Washington, D.C. 20231

CERTIFICATE OF MAILING BY EXPRESS MAIL	
"EXPRESS MAIL" Mailing Label No EI637428712US	
Date of Deposit December 3, 1997	
I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under	
37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for	
Patents, Box Patent Application, Washington, D.C. 20231	
Type or Print Name	A.M. (Andy) Ansmede, Jr.
..... <i>Andy A. Ansmede</i>	
Signature	

Dear Sir:

APPLICATION FOR U.S. PATENT TRANSMITTAL FORM

This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/032,329, filed December 3, 1996.

Transmitted herewith for filing are the following documents:

1. Application for "*Specific Antagonists for Glucose-Dependent Insulinotropic Polypeptide (GIP)*", including 23 pages of specification, 3 pages of claims (numbered 1-17), an Abstract (1 pg.), and 10 sheets of drawings (Figs. 1-9);
2. An Declaration and Power of Attorney (unexecuted);
3. A copy of the Verified Statement (Declaration) Claiming Small Entity Status (37 C.F.R. § 1.9(e) and §1.27(d)) - Nonprofit Organization, as filed on April 9, 1997;
4. A copy of the Notice of Recordation and Assignment as recorded on May 21, 1997 at Reel/Frame 8513/0911; and

Atty. Dkt. No.: 34477.2
USSN: Unassigned
Inventor: M. Michael Wolfe, *et al.*

5. Our check in the amount of \$595.00.

Fee Calculation

BASIC FEE			SMALL ENTITY RATE		LARGE ENTITY RATE		
			\$ 395.00	<u>OR</u>	\$	=	+\$ 395.00
	NUMBER FILED		NUMBER EXTRA				
TOTAL CLAIMS	17	-20	= 0 (at least 0)	x 11	<u>OR</u>	x 22	= +\$ 0.00
INDEP. CLAIMS	8	- 3	= 5 (at least 0)	x 40	<u>OR</u>	x 80	= +\$ 200.00
If any <u>proper</u> multiple dependent claim (ignore improper) is present (Enter \$0.00 if this is a <u>reissue</u> application.)			+\$130	<u>OR</u>	+\$260	=	+\$ 0.00
	TOTAL FILING FEE						=\$ 595.00

The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and may be required under 37 CFR 1.16-1.18 (missing or insufficiencies only) now or hereafter relative to this application and for the resulting Official Document under 37 CFR 1.20, and to have and cause any necessary petition for extension of time to be filed and any fees necessary to be paid for said extension of time OR credit any overpayment to our Deposit Account No. 10-0447/34477.2-PJM, for which purpose a duplicate copy of this sheet is attached. The Commissioner is not authorized to charge the issue fee until/unless an issue fee transmittal form is filed.

Atty. Dkt. No.: 34477.2
USSN: Unassigned
Inventor: M. Michael Wolfe, *et al.*

Please direct all future communication concerning this application to:

Peter J. Manso
Jenkens & Gilchrist, P.C.
1445 Ross Avenue
Suite 3200
Dallas, Texas 75202-2799

Respectfully submitted,

JENKENS & GILCHRIST, P.C.

Date: December 3, 1997

By: Peter J. Manso

Peter J. Manso
Reg. No. 32,264

*signed with permission by A.M. (Andy) Arismendi, Jr., Reg. No. 31,715



Jenkens & Gilchrist, P.C.
1445 Ross Avenue
Suite 3200
Dallas, Texas 75202
(713) 951-3375
(713) 951-3314 (fax)

**SPECIFIC ANTAGONISTS FOR GLUCOSE-DEPENDENT
INSULINOTROPIC POLYPEPTIDE (GIP)**

5

The work leading to this invention was supported in part by Grant Nos. DK08753 and RO1DK48042 from the National Institutes of Health. The U.S. Government may have certain rights to this invention.

10

Field of the Invention

This invention is directed to specific antagonists of glucose-dependent insulinotropic polypeptide (GIP). This invention is also directed to treatment of non-insulin dependent diabetes through increasing glucose tolerance without requirement for increased serum insulin, the treatment of obesity by the administration of a GIP antagonist, the development of nonpeptide GIP antagonist compounds, and compositions.

Background

Insulin release induced by the ingestion of glucose and other nutrients is due part to both hormonal and neural factors (Creutzfeldt, et al., 1985, *Diabetologia* **28**:565-573). Several gastrointestinal regulatory peptides have been proposed as incretins, the substance(s) believed to mediate the enteroinsular axis and that may play a physiological role in maintaining glucose homeostasis (Unger, et al., 1969, *Arch. Intern. Med.*, **123**:261-266; Ebert R., et al. 1987, *Diab. Metab. Rev.*, **3**:1-16; Dupré J., 1991, "The Endocrine Pancreas." Raven Press, New York, p 253). Among these candidates, only glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (7-36)(GLP-1) appear to fulfill the requirements to be considered physiological stimulants of postprandial insulin release (Dupré, et al. 1973, *J. Clin. Endocrinol. Metab.*, **37**:826-828; Nauck, et al., 1989, *J. Clin. Endocrinol. Metab.*, **69**:6540662; Kreymann, et al. 1987, *Lancet*, **2**:1300-1304; Mojsov, et al., 1987, *J. Clin. Invest.*, **79**:616-619).

Following oral glucose administration, serum GIP levels increase several fold (see Cleator, et al., 1975, *Am. J. Surg.*, **130**:128-135; Nauck, et al. 1986, *J. Clin. Endocrinol. Metab.*, **63**:492-498; Nauck, et al., 1986, *Diabetologia*, **29**:46-52; Salera, et al., 1983, *Metabolism*, **32**:21-24; Kreymann, et al., 1987, *Lancet*, **2**:1300-1304), and although the

0 9 8 0
1 5
2 0
2 5
3 0
3 5
4 0
4 5
5 0
5 5
6 0
6 5
7 0
7 5
8 0
8 5
9 0

increment in plasma GLP-1 concentration in response to glucose is also significant, it is far smaller in magnitude (Kreymann, et al., 1987, *Lancet*, **2**:1300-1304; Ørskov, et al., 1987, *Scand. J. Clin. Lab. Invest.*, **47**:165-174; Ørskov, et al., 1991, *J. Clin. Invest.*, **87**:415-423; Shuster, et al., 1988, *Mayo Clin. Proc.*, **63**:794-800). In human volunteers, Nauck *et al.* 5 (1993, *J. Clin. Endocrinol. Metab.*, **76**:912-917) showed that GIP was a major contributor in the incretin effect after oral glucose, whereas GLP-1 appeared to play a major role. Shuster *et al.* (1988) also suggested that GIP was the most important, but not the sole, mediator of the incretin effect in humans.

Some studies have demonstrated that GIP and GLP-1 are equally potent in their capacity to stimulate insulin release (Schmid, et al., 1990, *Z. Gastroenterol.*, **28**:280-284; Suzuki, et al., 1990, *Diabetes*, **39**:1320-1325), whereas others have suggested that GLP-1 possesses greater insulinotropic properties (Siegel, et al. 1992, *Eur. J. Clin. Invest.* **22**:154-157; Shima, et al. 1988, *Regul. Pept.*, **22**:245-252). Recently, using a putative specific antagonist to the GLP-1 receptor, exendin (9-39), Wang *et al.* have demonstrated that exendin reduced postprandial insulin release by 48% and thus concluded that GLP-1 might contribute substantially to postprandial stimulation of insulin secretion (Wang, et al. 1995, *J. Clin. Invest.*, **95**:417-421). More recent studies, however, have shown that exendin might also displace GIP binding from its receptor and thereby reduce GIP-stimulated cyclic adenosine monophosphate (cAMP) generation (Wheeler, et al. 1995, *Endocrinology*, **136**:4629-4639; Gremlich, et al. 1995, *Diabetes*, **44**:1202-1208). Therefore, the antagonist properties of exendin (9-39) might not be limited to GLP-1.

The availability of a GIP-specific receptor antagonist would be invaluable for determining the precise roles of these peptides in mediating postprandial insulin secretion.

25 **Summary of the Invention**

It is an object of this invention to provide specific antagonists of glucose-dependent insulinotropic polypeptide (GIP).

It is another object of this invention to provide alternative methods for treatment of non-insulin dependent diabetes which increase glucose tolerance without requirement for increased serum insulin, for treatment of obesity with a GIP antagonist which inhibits, blocks or reduces glucose absorption from the intestine of an animal, and for development of 30 nonpeptide GIP antagonist compounds.

In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24-amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP.

5 In another embodiment, this invention provides a method of treating non-insulin dependent diabetes mellitus in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

10 Using a reporter L-cell line stably transfected with rat GIP receptor cDNA (LGIPR2), the inventors have identified a fragment of GIP [GIP (7-30)-NH₂] as a specific GIP receptor antagonist. This antagonist (referred to as ANTGIP) inhibited GIP-stimulated intracellular cAMP production *in vitro*, and ANTGIP competed with GIP for binding to cellular receptors, but did not compete with GLP-1. ANTGIP inhibited the GIP-dependent release of insulin *in vivo*, but ANTGIP had no effect on glucose-, GLP-1-, GIP-, and arginine-induced insulin release in anesthetized rats. In conscious rats, ANTGIP inhibited postprandial insulin release, without significantly affecting the serum glucose concentration. However, despite its inhibiting effect on insulin release, ANTGIP has been discovered to enhance glucose tolerance in an oral glucose tolerance test.

Brief Description of the Figures

Figure 1A and 1B show cAMP-dependent β-galactosidase production by LGIPR2 cells in the presence of GIP or various GIP fragments.

25 Figure 2 shows dose-dependent inhibition of ANTGIP on GIP-included cAMP-dependent β-galactosidase production in LGIPR2 cells.

Figure 3 shows competition of ¹²⁵I-GIP and ¹²⁵I GLP-1(inset) binding by GIP, GLP-1 and ANTGIP.

Figure 4 shows plasma insulin concentrations (±SE) in fasted anesthetized rats after 30 min of GIP, ANTGIP, or 0.9 NaCl infusion.

30 Figure 5 shows plasma insulin concentrations (±SE) in fasted anesthetized rats after a 30-min infusion of GLP-1 (0.4 nmol/kg), glucose (0.8 g/kg), or arginine (375 mg/kg) with (open bars) or without (solid bars) ANTGIP (100 nmol/kg) (n=6 for each group).

Figure 6 shows postprandial plasma insulin and serum glucose levels (\pm SE) in conscious trained rats.

Figure 7 shows plasma insulin level following oral glucose administration to rats with or without ANTGIP injection.

5 Figure 8 shows plasma glucose level following oral glucose administration to rats with and without ANTGIP injection.

Figure 9 shows the effects of the GIP receptor antagonist, ANTGIIP, on the absorption of free D-glucose from the lumen of the jejunal test segment.

10 **Detailed Description of the Invention**

Glucose-dependent insulinotropic polypeptide (GIP) is 42-amino acid hormone that was originally described as a inhibitor of acid secretion. More recently, however, it has been shown to be potent stimulant for the release of insulin from the endocrine pancreas.

The inventors have confirmed previous studies (Rossowski, et al., 1992, *Regul. Pep.*, 39:9-17) indicating that truncated GIP [GIP (1-30)-NH₂] might be one of the biologically active forms of mature GIP. As shown in Figure 1, GIP (1-30)-NH₂ was nearly equipotent to GIP (1-42) in stimulating cAMP dependent β -galactosidase production in LGIPR2 cells. These findings are consistent with the observations of Wheeler, et al. (1995), reported that both GIP(1-42) and GIP(1-30) exhibited similar stimulatory properties for cAMP production in COS-7 cell transiently expressing GIP receptor cDNA. Moreover, Kieffer et al. (1993, *Can. J. Physiol. Pharmacol.*, 71:917-922) found that GIP (1-30) competitively inhibited binding of GIP (1-42) to the GIP receptor in β TC3 cells. These data suggest the possibility of cellular processing of GIP (1-42) to yield biologically-active α -amidated GIP (1-30).

25 **Physiological effects of GIP antagonists**

Insulin release induced by the ingestion of glucose and other nutrients is due in part to both hormonal and neural factors (see, e.g., Creutzfeldt, et al., 1985). Although a number of gastrointestinal regulatory peptides have been proposed as putative incretins, GIP and GLP-1 are the most likely physiological insulinotropic peptides. Although both GIP and GLP-1 possess significant insulinotropic properties, controversy exists regarding their relative physiological roles in stimulating insulin release.

Using a GLP-1 receptor antagonist exendin (9-39), Wang *et al.* (1995) detected a 50% decrease in postprandial insulin secretion in exendin-treated rats. Administration of exendin also reduced 70% of insulin release following intraduodenal glucose infusion (Kolligs, et al., 1995, *Diabetes*, **44**:16-19). Recent studies, however, have demonstrated that exendin also displaced GIP binding from its receptor, and inhibits cAMP generation in response to GIP stimulation (Wheeler, et al. 1995; Gremlich, et al. 1995). Therefore, the antagonist properties of exendin do not appear to be GLP-1 specific.

Successful synthesis by the present inventors of a specific GIP receptor antagonist greatly facilitates investigation of the relative contribution of GIP in mediating the enteroinsular axis. The GIP fragment ANTGIP [GIP (7-30)-NH₂] specifically inhibits various GIP-dependent effects. In LGIPR2 cells, ANTGIP inhibited the cAMP response to GIP in a concentration-dependent manner (see Figure 2), and in β TC3 cells, the antagonist displaced GIP binding from its receptor (see Figure 3). Furthermore, ANTGIP completely abolished the insulinotropic properties of GIP in fasted anesthetized rats, while not affecting GLP-1, glucose-, or arginine-stimulated insulin release indicating that this antagonist is GIP-specific. ANTGIP alone demonstrated no stimulatory effect on insulin release or cAMP generation in either intact rats or LGIPR2 cells, indicating the absence of any agonist properties. Studies demonstrated that even at a concentration as high as 10⁻⁴ M, ANTGIP did not stimulate a detectable increase in cAMP-dependent β -galactosidase level in LGIPR2 cells.

The inventors have observed a 72% decrease in postprandial insulin release in response to the administration of ANTGIP to rats. ANTGIP did not affect GLP-1 binding to its receptor, and the insulinotropic effect of GLP-1 is preserved *in vivo* in the presence of ANTGIP. Furthermore, postprandial GLP-1 levels were not affected by ANTGIP. These findings are consistent with a dominant role for GLP in mediating the enteroinsular axis.

Wang *et al.* demonstrated an approximate 50% reduction in postprandial insulin levels in exendin-treated rats, whereas plasma glucose levels increased minimally from 7.5 to 8.7 mmol/l. The physiological significance of this minor increment in glucose level was not clear to Wang, et al. The inventors found that serum glucose concentrations remained largely unchanged despite a marked decrease in serum insulin levels in ANTGIP-treated rats. The results of the present study are consistent with the notion that insulin is not the sole mediator of glucose homeostasis, but that glucose maintenance is dependent on numerous neurohumoral factors. These factors include hormones, such as pancreatic glucagon, cortisol,

and growth hormone, and physiological events, including peripheral and hepatic glucose uptake.

The results of the present studies demonstrate that GIP (7-30)-NH₂ is a specific receptor antagonist of naturally occurring GIP. GIP (7-30)-NH₂ inhibits GIP-induced cAMP generation and insulin release, but does not affect the insulinotropic effects of other secretagogues such as glucose, arginine, and GLP-1. Furthermore, circulating insulin levels decreased by 72% in response to the concomitant administration of GIP (7-30)-NH₂ to chow-fed rats, indicating that GIP plays a dominant role in mediating postprandial insulin secretion.

Strikingly, although GIP (7-30)-NH₂ reverses the insulin stimulatory properties of the parent compound, when the GIP antagonist was administered to rats (injected intraperitoneally), oral glucose tolerance was improved: a significant decrease in serum glucose levels was detected at all time points in all rats. In addition, plasma insulin levels were also diminished in these same rats. These results are surprising -- with the decrease in insulin release, one would expect an increase in serum glucose. However, GIP has several other peripheral effects which may include an effect of GIP on peripheral glucose utilization, and the decrease in serum glucose levels seen with GIP might be due to such an effect.

The effect of GIP antagonists on serum glucose levels in the absence of increased serum insulin suggests their use in patients with noninsulin dependent diabetes mellitus (NIDDM). With the aging of the United States population, an increase in the number of cases of NIDDM has been predicted. In the past forty years, very few new forms of therapy for this most prevalent disease have been developed. GIP antagonists enhance tolerance to oral glucose, as demonstrated herein, and therefore treatment of NIDDM patients with these compounds is indicated.

25 **GIP Antagonists**

A GIP antagonist according to this invention is any composition which interferes with biological action of GIP. Such compositions include antibodies specific for either GIP or GIP receptors, antisense RNA which hybridizes with mRNA encoding GIP or GIP receptor, or other genetic controls which knock out expression of GIP or GIP receptor. GIP antagonists also include peptides or other small molecules which bind to the GIP receptor and block the cAMP response to GIP. Suitable assays for antagonist activity are exemplified in Examples 1 and 2 below:

As described herein (see Example 1 below), the inventors have now discovered a polypeptide fragment of GIP that is a specific GIP receptor antagonist. While the 30-amino acid N-terminal fragment [GIP (1-30)-NH₂] was as effective in stimulating cAMP increase through GIP receptors as the parent hormone, a fragment missing the most N-terminal six amino acids [GIP (7-30)-NH₂] did not stimulate cAMP release in the same system. Thus, the N-terminal hexamer appears to be important for functional GIP signaling. GIP fragments missing the N-terminal 15 amino acids (e.g., GIP (16-30)-NH₂) did not mimic GIP, but neither did they inhibit GIP-dependent effects. Thus, the segment from amino acids 7-15 appears to be especially important in signaling through the GIP receptor. Fragment GIP (10-30)-NH₂ was less effective as an antagonist, but retained some ability to affect GIP receptor activation, as indicated by partial agonist activity. Thus, peptide antagonists would appear to require the segment from amino acids 7-9 of the GIP sequence, and some or all of the amino acids from 10-30 or effective alternative amino acids thereto are likely to promote binding to the receptor. It should therefore be understood by those of skill in this art that the present invention contemplates any polypeptide sequence which effectively prevents GIP activation of its native receptor, such as the sequence containing amino acids in positions 7-30 of the sequence of the GIP sequence and polypeptides based upon sequences containing amino acids in positions 7-30 of the sequence of the GIP that include additional, deleted or alternative amino acids to form effective GIP polypeptide antagonist. Polypeptides based on this sequence may be designed for use as GIP antagonists according to this invention by the skilled artisan, who will routinely confirm that the resultant peptides exhibit antagonist function by testing the peptides in *in vitro* and *in vivo* assays such as those described in Examples 1 and 3-5 below.

Immunologic components specific for GIP or GIP receptors can be employed as GIP antagonists. Such antagonists include with specific monoclonal antibodies (either naked or conjugated to cytotoxic agents) or specific activated cytotoxic immune cells. Such antibodies or immune cells may be generated as reagents outside the body, or may be generated inside the body by vaccines which target GIP or GIP receptors.

Antibodies which are specifically reactive with GIP or the hormone binding domain of GIP receptor, or antigenic recombinant peptide fragments of either of those proteins, may be obtained in a number of ways which will be readily apparent to those skilled in the art. The known sequences of GIP (see Takeda, et al. 1987, *Proc. Natl. Acad. Sci USA*, B84:7005-

7008, and Genbank Accession No. M18185), and GIP receptor (see Bonner, T.I., and Usdin, T.B., 1995, Genbank Accession No U39231) can be used in conjunction with standard recombinant DNA technology to produce the desired antigenic peptides in recombinant systems (see, e.g., Sanbrook et al.). Antigenic fragments of GIP or GIP receptor can be injected into an animal as a immunogen to elicit polyclonal antibody production. Purification of the antibodies can be accomplished by selective binding from the serum, for instance by using cells transformed with DNA sequence encoding the respective proteins. The resultant polyclonal antisera may be used directly or may be purified by, for example, affinity absorption using recombinantly produced protein coupled to an insoluble support.

10 In another alternative, monoclonal antibodies specifically immunoreactive with either GIP or the hormone binding domain of GIP receptor may be prepared according to well known methods (See, e.g., Kohler and Milstein, 1976, *Eur. J. Immunol.*, 6:611), using the proteins or antigenic fragments described above as immunogen(s), using them for selection or using them for both functions. These and other methods for preparing antibodies or immune cells that are specifically immunoreactive with GIP or GIP receptor are easily within the skill of the ordinary worker in the art.

15 Immunogenic compositions according to this invention for use in active immunotherapy include recombinant antigenic fragments of GIP or GIP receptor prepared as described above and expression vectors (particularly recombinant viral vectors) which express antigenic fragments of GIP or GIP receptor. Such expression vectors can be prepared as described in Baschang, et al., U.S. Patent No. 4,446,128, incorporated herein by reference, or Axel, et al., Pastan, et al., or Davis, et al., using the known sequences of GIP or GIP receptor.

20 Still another GIP antagonist according to this invention is an expression vector containing an antisense sequence corresponding to all or part of an mRNA sequence encoding GIP or GIP receptor, inserted in opposite orientation into the vector after a promoter. As a result, the inserted DNA will be transcribed to produce an RNA which is complementary to and capable of binding or hybridizing to the mRNA. Upon binding to the GIP or GIP receptor mRNA, translation of the mRNA is prevented, and consequently the protein coded for by the mRNA is not produced. Suitable antisense sequences can be readily selected by the skilled artisan from the 25 sequences of GIP or GIP receptor cited above. Production and use of antisense expression vectors is described in more detail in U.S. Patent 5,107,065 and U.S. Patent 5,190,931, both of which are incorporated herein by reference.

Alternative materials within the contemplation of the skilled artisan which function as antagonists of GIP in the procedures described in Examples 1 and 3-5 below may also be used in the therapeutic methods according to this invention.

5 **Therapeutic use of GIP antagonists**

GIP (7-30)-NH₂ acts as a receptor antagonist of GIP, but also improves glucose tolerance contrary to the expected consequence of blocking GIP-dependent insulin secretion. In addition, a GIP receptor antagonist in accordance with the present invention inhibits, blocks or reduces glucose absorption from the intestine of an animal. In accordance with this observation, 10 therapeutic compositions containing GIP antagonists may be used in patients with noninsulin dependent diabetes mellitus (NIDDM) to improve tolerance to oral glucose or in animals, such as humans, to prevent, inhibit or reduce obesity by inhibiting, blocking or reducing glucose absorption from the intestine of the animal, as demonstrated herein.

Therapeutic compositions according to this invention are preferably formulated in pharmaceutical compositions containing one or more GIP antagonists and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain other components so long as the other components do not reduce the effectiveness of the GIP antagonist according to this invention so much that the therapy is negated. Examples of such components include sweetening, flavoring, coloring, dispersing, disintegrating, binding, granulating, suspending, wetting, preservative and demulcent agents and the like. Pharmaceutically acceptable carriers are well known, and one skilled in the pharmaceutical art can easily select carriers suitable for particular routes for administration (Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 1985).

Also in accordance with the present invention, the GIP receptor antagonist of the present invention may be lyophilized using standard techniques known to those in this art. The lyophilized GIP receptor antagonists may then be reconstituted with, for example, suitable diluents such as normal saline, sterile water, glacial acetic acid, sodium acetate, combinations thereof and the like. The reconstituted GIP receptor antagonists in accordance with the present invention may be administered parenterally or orally and may further include preservatives or other acceptable inert components as mentioned hereinbefore.

The pharmaceutical compositions containing any of the GIP antagonists according to this invention may be administered by parenteral (subcutaneously, intramuscularly, intravenously,

intraperitoneally, intrapleurally, intravesicularly or intrathecally, topical, oral, rectal, or nasal route, as necessitated by choice of drug and disease. The dose used in a particular formulation or application will be determined by the requirements of the particular state of disease and the constraints imposed by the characteristics of capacities of the carrier materials. The
5 concentrations of the active agent in pharmaceutically acceptable carriers may range from 0.1nM to 100 μ M. The compositions described above may be combined or used together or in coordination with another therapeutic substance.

Dose will depend on a variety of factors, including the therapeutic index of the drugs, disease type, patient age, patient weight, and tolerance of toxicity. Dose will generally be chosen
10 to achieve serum concentrations fro about 0.1 μ g/ml to about 100 μ g/ml. Preferably, initial dose levels will be selected based on their ability to achieve ambient concentrations shown to be effective in in-vitro models, such as that used to determine therapeutic index, and in-vivo models and in clinical trials, up to maximum tolerated levels. Standard clinical procedure prefers that chemotherapy be tailored to the individual patient and the systemic concentration of the chemotherapeutic agent be monitored regularly. The dose of a particular patient can be determined by the skilled clinician using standard pharmacological approaches in view of the above factors. The response to treatment may be monitored by analysis of blood or body fluid levels of the glucose or GIP or GIP antagonist according to this invention, measurement of activity if the antagonist or its levels in relevant tissues or monitoring disease state of the patient. The skilled clinician will adjust the dose based on the response to treatment revealed by these measurements.

One approach to therapy of NIDDM is to introduce vector expressing antisense sequences to block expression of GIP and/or GIP receptor. In one embodiment of this invention, a method is provided which comprises obtaining a DNA expression vector containing a cDNA sequence
25 having the sequence of human GIP or GIP receptor mRNA which is operably linked to a promoter such that it will be expressed in antisense orientation, and transforming cells which express GIP or GIP receptor, respectively, with the DNA vector. The expression vector material is generally produced by culture of recombinant or transfected cells and formulated in a pharmacologically acceptable solution or suspension, which is usually a physiologically-
30 compatible aqueous solution, or in coated tablets, tablets, capsules, suppositories, inhalation aerosols, or ampules, as described in the art, for example in U.S. Patent 4,446,128, incorporated herein by reference.

The vector-containing composition is administered to a mammal exhibiting NIDDM in an amount sufficient to transect a substantial portion of the target cells of the mammal. Administration may be any suitable route, including oral, rectal, intranasal or by intravesicular (e.g. bladder) instillation or injection where injection may be, for example, transdermal, 5 subcutaneous, intramuscular or intravenous. Preferably, the expression vector is administered to the mammal so that the target cells of the mammal are preferentially transfected. Determination of the amount to be administered will involve consideration of infectivity of the vector, transection efficiency *in vitro*, immune response of the patient, etc. A typical initial dose for administration would be 10-1000 micrograms when administered intravenously, intramuscularly, subcutaneously, 10 intravesicularly, or in inhalation aerosol, 100 to 1000 micrograms by mouth, 10^5 to 10^{10} plaque forming units of a recombinant vector, although this amount may be adjusted by a clinician doing the administration as commonly occurs in the administration of other pharmacological agents. A single administration may usually be sufficient to produce a therapeutic effect, but multiple administrations may be necessary to assure continued response over a substantial period of time.

SEARCHED
INDEXED
COPIED
FILED

Further description of suitable methods of formulation and administration according to this invention may be found in U.S. Patents 4,592,002 and 4,920,209, which are incorporated herein by reference in their entireties.

The present invention also contemplates the use of the GIP antagonists and/or its properties to develop nonpeptide compounds which exhibit antagonist properties similar to the GIP polypeptide antagonists as herein described using techniques known to those versed in the pharmaceutical industry.

Examples

In order to facilitate a more complete understanding of the invention, a number of Examples are provided below. However, the scope of the invention is not limited to specific 25 embodiments disclosed in these Examples, which are for purposes of illustration only.

Example 1

Effects of Various Peptide Fragments on cAMP Production

30

To define the biologically active region of GIP, the effects of several peptide fragments of GIP on stimulating cAMP-dependent β -galactosidase production in LGIPR2 cells were

examined. LGIPR2 cells are stably transfected with a cAMP-dependent promoter from the VIP gene fused to the bacterial *lac Z* gene. When intracellular cAMP increases within these cells, *lac Z* gene transcription is activated, resulting in the accumulation of its product, β -galactosidase. The measurement of β -galactosidase in this system provided a convenient, inexpensive, and

5 nonradioactive method for detecting changes in the levels of intracellular cAMP.

LGIPR2 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) containing 4.5 g/L of glucose and 10% fetal calf serum. For each assay, 10^5 cells/well were seeded onto 24-well plates. After incubation overnight, peptides were added in various concentrations to the wells in the absence of 3-isobutyl-methylxanthine (IBMX) for 4 h, at which time maximal

10 stimulation of β -galactosidase was determined. The medium was then removed and wells rinsed once with phosphate-buffered saline (PBS). The plates were then blotted briefly and frozen overnight at -70°C, and, after the addition of chlorophenol red- β -D-galactopyranoside, accumulated β -galactosidase was detected using a colorimetric assay, as described previously

15 (Usdin, et al., 1993, *Endocrinology*, **133**:2861-2870).

bioRxiv preprint doi: https://doi.org/10.1101/2023.06.05.536025; this version posted June 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

20

25

Preliminary studies using LGIPR2 cells demonstrated that GIP(1-42) stimulated β -galactosidase production in a concentration-dependent manner, with the maximum effect observed at 4 h with 10^{-8} M. Various peptide fragments of GIP, including GIP(21-30)NH₂, GIP (16-30)-NH₂, GIP (7-30)-NH₂, GIP (1-30)-NH₂, GIP (10-30)-NH₂, and GIP (31-44), were synthesized at the Biopolymer Laboratory, Harvard Medical School, based on previously published rat GIP cDNA sequence (Tseng, et al., 1993, *Proc. Natl. Acad. Sci. USA*, **90**:1992-1996). LGIPR2 cells were incubated in the presence of 10^{-8} M GIP or different GIP fragments for 4 h, and β -galactosidase was measured as described herein and expressed in optical density (O.D.) units. Figure 1A and 1B show cyclic AMP-dependent β -galactosidase generation in LGIPR2 cells in response to incubation with different fragments of GIP. Values are expressed as the mean \pm SE of quadruplicate measurements (*p < 0.01, compared to control).

30

As demonstrated in Figure 1A, 10^{-8} M GIP (1-30)-NH₂ stimulated β -galactosidase production to a similar degree, while none of the other peptide fragments tested, including GIP (7-30)-NH₂, GIP (16-30)-NH₂, GIP (21-30)-NH₂, and GIP (31-44), stimulated β -galactosidase generation above control levels. Furthermore, no changes in cAMP-dependent- β -galactosidase levels were detected when LGIPR2 cells were incubated in the presence of higher concentrations of the smaller peptide fragments.

To examine whether any of these fragments might serve as an antagonist to GIP, LGIPR2 cells were incubated with 10^{-8} M GIP (1-42) and one of the peptide fragments at two different concentrations (10^{-8} M or 10^{-6} M) for 4 h. LGIPR2 cells were cultured in the presence of 10^{-8} M GIP and various concentrations of ANTGIP, as depicted on the horizontal axis if Figure 2.

Values are expressed as the mean \pm SE of quadruplicate measurements. Only GIP (7-30)-NH₂ (ANTGIP) was found to attenuate the cAMP stimulatory effects exhibited by GIP (1-42); the inhibition was concentration-dependent, with half-maximal inhibition occurring at 10^{-7} M (Figure 2).

Figure 1B shows that peptide GIP (10-30)-NH₂ is an antagonist, albeit a weak one, as demonstrated by the reduction in GIP-stimulated β -gal levels when GIP (10-30)-NH₂ is present with GIP (1-42) compared to GIP (1-42) alone. On the other hand, GIP (10-30)-NH₂ also has agonist properties, as demonstrated by β -gal level of $0.39 \text{ O.D.} \pm 0.03$ stimulated by GIP (10-30)-NH₂ alone, compared to 0.95 ± 0.04 for GIP (1-42).

dRAFTED BY DR. J. R. HARRIS

Example 2

Receptor Binding Studies

Binding studies were performed in either LGIPR2 or β TC3 cells to determine the relative affinities of GIP, ANTGIP, and GLP-1 for both GIP and GLP-1 receptors. GLP(7-37) and porcine GIP (5 μ g each) were iodinated by the chloramine-T method and were purified using C-18 cartridges (Sep-Pak®, Millipore, Milford, MA) using an acetonitrile gradient of 30-45%. The specific activity of radiolabeled peptides was 10-50 μ Ci/mg (Hunter, et al., 1962, *Nature*, 194:495-498; Kieffer, et al., 1993, *Can. J. Physiol. Pharmacol.*, 71:917-922). Aliquots were lyophilized and reconstituted in assay buffer at 4°C to a concentration of 3×10^5 cpm/100 μ l. Binding studies was performed in desegregated LGIPR2 or β TC2 cells, the latter a generous gift from Dr. S. Efrat (Diabetes Center, Albert Einstein College of Medicine, New York). The β TC2 cell line originally arose in a lineage of transgenic mice expressing an insulin promoted, SV40 T-antigen hybrid oncogene in pancreatic β -cells (Efrat, et al., 1988, *Proc. Natl. Acad. Sci. U.S.A.*, 85:9037-9041) and has previously been demonstrated to be responsive to both GIP and GLP (Kieffer, et al., 1993, *Can. J. Physiol. Pharmacol.*, 71:917-922). The receptor binding buffer contained 138 mM NaCl, 5.6 mM KCl, 1.2 mM MgCl₂, 2.6 mM CaCl₂, 10 mM Hepes, 10 mM glucose, and 1% bovine serum albumin (BSA, fraction V, protease free, Sigma). For binding assays, LGIPR2 (GIP binding) or β TC3 (GLP-1 binding) cells were cultured in DMEM containing 4.5 g/L of glucose and 10% fetal bovine serum until 70% confluent. Cells were washed once with PBS and then harvested with PBS-EDTA solution. β TC3 cells were then suspended in assay buffer at a density of 2×10^6 cells/ml, and LGIPR2 cells were used at a density of 2.5×10^5 cells/ml. Binding was performed at room temperature in the presence of 3×10^5 cpm/ml of [¹²⁵I]- GIP and -GLP. Nonsaturable binding was determined by the amount of radioactivity associated with cells when incubated in the presence of unlabeled 10^{-6} M GIP, GLP, or 10^{-4} M ANTGIP. Specific binding was defined as the difference between counts in the absence and presence of unlabeled peptide. GIP binding was examined using LGIPR2 cells, and GLP-1 binding was assessed using β TC3 cells, and the results are shown in Figure 3. Values are expressed as a percentage of maximum specific binding and are the mean \pm SE, with assays performed in duplicate.

GIP and ANTGIP displaced the binding of [¹²⁵I]GIP to LGIPR2 cells in a concentration-dependent manner (Fig. 3), with an IC₅₀ of 7 nM for GIP (n=5) and 200 nM for ANTGIP (n=4).

Binding of [¹²⁵I]GLP-1 to its β TC3 cell receptor was displaced fully by GLP-1, but negligibly by ANTGIP, with an IC₅₀ of 4 nM and 80 μ M, respectively (n=7; Fig. 3).

Example 3

5 Intravenous Infusion of Peptides in Fasting Anesthetized Rats

Adult male Sprague-Dawley rats (250-350 g) were purchased from Charles River Co. (Kingston, MA). For infusion studies, rats were fasted overnight and then anesthetized using intraperitoneal sodium pentobarbital. The right jugular vein was cannulated with silicon polymer tubing (0.025 in I.D., 0.047 in O.D., Dow Corning Corporation, Midland, MI), as described by Xu and Melethil (21). The tubing was then connected to an infusion pump (Harvard Apparatus Co., Inc., Millis, MA), and freshly made 0.9% NaCl, 5% glucose, arginine, GIP, or GLP-1 (peptides and arginine dissolved in 0.9% NaCl) was infused at a rate of 0.1 ml/min. Blood (0.5 ml each) was obtained at 0, 10, 20, and 30 min by translumbar vena cava puncture, as described by Winsett *et al.* (1985, *Am. J. Physiol.*, **249**:G145-146), and samples were centrifuged at 2,000 g for 10 min. Serum samples were separated and stored at -20°C until assayed for insulin using a radioimmunoassay kit (ICN Biochemicals, Costa Mesa, CA), and glucose, using a One Touch Li β glucose meter (Lifescan, INS., Milpitas, CA).

To examine the insulinotropic effect of GIP *in vivo*, fasted anesthetized rats were perfused continuously with three different concentrations of GIP (0.5, 1.0, and 1.5 nmol/kg) at a rate of 0.1 ml/min for 30 min (10^{-8} M equivalent to 1 nmol/kg/30 min). Significant increases in plasma insulin levels were first detected at 15 min, and after completion of the GIP infusion, insulin levels were elevated with all three GIP concentrations (43.5 ± 2.7 , 61.6 ± 4.2 , and $72.4 \pm 3.5 \mu$ IU/ml, respectively) compared to control ($32.2 \pm 3.3 \mu$ IU/m, p<0.05, Fig. 4). The concomitant administration of ANTGIP (100 nmol/kg) completely abolished the insulinotropic properties of GIP (1.5 nmol/kg), with plasma insulin returning to control values (Fig. 4). GIP was infused at 0.5, 1.0, and 1.5 nmol/kg, with the largest insulin stimulatory response seen with 1.5 nmol/kg. ANTGIP (100 nmol/kg) administered concomitantly with GIP 1.5 nmol/kg completely abolished its insulinotropic effect, whereas ANTGIP and 0.9% NaCl infusion had no effect on insulin secretion (n=6 for each group, *p <0.05, compared with basal levels).

To examine whether ANTGIP exerted a nonspecific effect on β -cell function, GLP-1 (0.4 nmol/kg), glucose (0.8 g/kg), or arginine (375 mg/kg) was infused, in the presence or absence of

the antagonist for 30 min, as described by Wang et al. (13). Figure 5 shows plasma insulin concentrations (\pm SE) in fasted anesthetized rats after a 30-min infusion of GLP-1 (0.4 nmol/kg), glucose (0.8 g/kg), or arginine (375 mg/kg) with (open bars) or without (solid bars) ANTGIP (100 nmol per kg) (n=6 for each group, *p <0.05, compared with basal levels). GLP-1, glucose, and arginine alone each significantly increased insulin levels after 15 min of infusion, and by 30 min, the insulin levels in GLP-1-, glucose-, and arginine-infused rats were 50.3 ± 3.7 , 63.1 ± 2.5 , $69.7 \pm 5.8 \mu\text{IU}/\text{ml}$ respectively (p < 0.01, compared with control rats, $29.1 \pm 2.9 \mu\text{IU}/\text{ml}$, Fig. 5). No significant change in the insulin response was detected when ANTGIP was administered concomitantly (Fig. 5).

10

Example 4

Insulinotropic Effect of GIP in Trained Conscious Fed Rats

Postprandial plasma insulin and serum glucose levels were studied in conscious trained rats. Previous reports have indicated that the stress response to injection in untrained rats might alter their feeding and subsequently glucose and insulin levels (13). To avoid such a response, rats were trained for 10 d before experimentation. They were fasted from 17:00 to 08:00, and 0.9% NaCl (0.3ml) was injected subcutaneously at 08:00 before feeding. After the injection of 0.9% NaCl, animals were given rat chow for 30 min, after which it was removed. At the end of ten days, the rats were accustomed to the injection and ate quickly (consuming 4-6g of rat chow within 30 min).

25

On the day of the experiment, after fasting from 17:00 the night before, trained rats were injected subcutaneously at 08:00 with 0.3 ml of either 0.9% NaCl or ANTGIP (100 nmol/kg). This dose was chosen to approximately the amount of peptide used in the anesthetized animal studies of Example 3. After injection, six of the fasted control rats were killed to obtain baseline serum glucose and insulin levels. ANTGIP- or 0.9% NaCl-treated rats (n=6 in each group) were exposed to chow for 30 min, after which food was withdrawn. Rats were then anesthetized by intraperitoneal sodium pentobarbital, and blood was collected by translumber vena cava puncture at 20 and 40 min for the subsequent measurement of plasma insulin, glucose, and GLP-1.

30

Figure 6 shows postprandial plasma insulin and serum glucose levels (\pm SE) in conscious trained rats (* p < 0.01 compared to ANTGIP injection). In response to consuming chow, serum glucose and plasma insulin levels increased significantly, with insulin levels of 38.7 ± 5.3 and 58.9

PCTC-15
15
20
25
30

$\pm 3.7 \mu\text{IU}/\text{ml}$ at 20 and 40 min, respectively ($p < 0.05$, Fig. 6A). These increases in plasma insulin level were nearly abolished by ANTGIP pretreatment; at 20 and 40 min, the plasma insulin concentrations were 25.3 ± 4.7 and $27.1 \pm 2.6 \mu\text{IU}/\text{ml}$, respectively ($p < 0.01$). Postprandial serum glucose concentrations were similar in both saline- and ANTGIP-treated rats (Fig. 6B).

To determine whether the effects of the GIP receptor antagonist were mediated through changes in GLP-1 release into the circulation, postprandial serum GLP-1 levels were measured in both control and ANTGIP-treated animals. Meal-stimulated serum GLP-1 concentrations were not affected by ANTGIP administration. Following the ingestion of rat chow, serum GLP-1 levels at 20 min were 280 ± 20 and $290 \pm 10 \text{ pg}/\text{ml}$ in control and ANTGIP-treated rats, respectively; at 40 min, serum GLP-1 concentrations were 320 ± 10 and $330 \pm 20 \text{ pg}/\text{mgl}$, respectively.

Example 5

Effect of ANTGIP on Glucose Tolerance and Plasma Insulin Levels

Oral glucose tolerance tests were performed on rats injected intraperitoneally with ANTGIP (300 ng/kg) or 0.9% saline solution. After the intraperitoneal injection of 0.9% NaCl or ANTGIP, an oral glucose tolerance test was performed. The test was done by administering a 40% glucose solution by oral gavage at a dose of 1 g per kg. The volume administered to each rat was approximately 0.5 ml. Blood was obtained at various time points for subsequent measurement of plasma insulin and glucose levels.

As expected in view of the experiment in Example 4, rats treated with ANTGIP showed reduced the plasma insulin levels (Figure 7). Surprisingly, plasma glucose was diminished at all time points in rats treated with ANTGIP, compared to control rats (Figure 8). Thus, ANTGIP increases glucose tolerance, despite its negative effect on the insulinotropic response to GIP shown in Examples 3 and 4.

Example 6

Effect of GIP Receptor Antagonist on Intestinal Glucose Absorption

Male Sprague-Dawley rats weighing about 200-250 g are fasted overnight and anesthetized using intraperitoneal urethane (about 1.25 g per kg body weight). After midline laparotomy, an about 30-cm segment of jejunum, starting at about 5 cm distal to the ligament of

Treitz, is isolated and flushed with approximately 20 ml of about 0.9% NaCl. The jejunal test segments are each perfused twice, initially with control buffer and then once again with control buffer or with the test solution. The test solution consists of Krebs-Ringer-bicarbonate buffer containing about 5 mmol/L [¹⁴C]D-glucose, and ³H-labeled polyethylene glycol is included in the
5 luminal perfusate to correct for fluid movement. The test or control solution is perfused through the jejunal segment without recirculation at a flow rate of about 1.6 ml/min, using a Harvard PHD 2000 syringe pump (Harvard Apparatus, Millis, MA). The effluent from the luminal segment is collected at about 5-min intervals for about 30 min. After the initial period of perfusion, the
10 luminal contents in the jejunum are flushed with about 20 ml of about 0.9% NaCl prior to the initiation of the second period of perfusion. In all experiments, animals are administered either about 0.9% NaCl (control) or ANTGIP (10 nmol/kg body weight) though the inferior vena cava by single injection at about time 0 min.

DRAFT-2015-06-20

The enclosed Figure 9 depicts the effects of the GIP receptor antagonist, ANTGIP, on the absorption of free D-glucose from the lumen of the jejunal test segment. Data points are believed to represent the rate of glucose disappearance from the luminal perfusate corrected for fluid movement. Results are expressed as the mean ±SE of five experiments. Statistical significance (*) is assigned if P < 0.05. As seen in the figure, a ANTGIP is believed to significantly reduce the absorption of D-glucose from the jejunal test segment throughout the entire 30-mini period of perfusion. Thus, it is believed that one of the mechanisms by which GIP receptor antagonism may improve glucose tolerance is by decreasing intestinal glucose absorption.

For purposes of clarity of understanding, the foregoing invention has been described in some detail by way of illustration and example in conjunction with specific embodiments, although other aspects, advantages and modifications will be apparent to those skilled in the art to which the invention pertains. The foregoing description and examples are intended to illustrate, but not
25 limit the scope of the invention. Modifications of the above-described modes for carrying out the invention that are apparent to persons of skill in medicine, molecular biology, pharmacology, and/or related fields are intended to be within the scope of the invention, which is limited only by the appended claims.

All publications and patent applications mentioned in this specification are indicative of
30 the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference in their entireties to the same extent as

if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Having describe our invention, we claim:

5 (1) An antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP.

10 (2) A method of treating non-insulin dependent diabetes mellitus in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

15 (3) A method of improving glucose tolerance in a non-insulin dependent diabetes mellitus patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

20 (4) A method of preventing, inhibiting or reducing obesity in an animal comprising administering to the animal an antagonist of glucose-dependent insulinotropic polypeptide (GIP) to inhibit, block or reduce glucose absorption from the intestine of the animal.

25 (5) A method according to claim 4, wherein the animal is a human.

30 (6) A method according to claim 4, wherein the antagonist comprises at least an effective number of amino acids corresponding to those amino acids in positions 7-30 of the sequence of GIP or effective alternative sequences thereto.

35 (7) A method according to claim 5, wherein the antagonist comprises a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP or effective alternative sequences thereto.

40 (8) An antagonist of glucose-dependent insulinotropic polypeptide (GIP).

45 (9) An antagonist according to claim 8, wherein said antagonist comprises at least an effective number of amino acids corresponding to those amino acids in posts 7-30 of the sequence of GIP or effective alternative sequences thereto.

(10) An antagonist according to claim 8, wherein said antagonist comprises a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP or effective alternative sequences thereto.

5 (11) A pharmaceutical composition for preventing, inhibiting or reducing obesity in an animal comprising:

an effective amount of an antagonist of glucose-dependent insulinotropic polypeptide (GIP) to inhibit, block or reduce glucose absorption from the intestine of the animal; and

10 an acceptable pharmaceutical carrier.

15 (12) A pharmaceutical composition according to claim 11, wherein the antagonist comprises at least an effective number of amino acids corresponding to those amino acids in positions 7-30 of the sequence of GIP or effective alternatives thereto.

20 (13) A pharmaceutical composition according to claim 11, wherein the antagonist comprises a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP or effective alternatives thereto.

25 (14) A pharmaceutical composition according to claim 11, said pharmaceutical composition further including an inert pharmaceutical excipient selected from the group consisting of sweetening, flavoring, coloring, dispersing, disintegrating, binding, granulating, suspending, wetting, preservative and demulcent agents.

30 (15) An antagonist according to claim 8, wherein the antagonist is lyophilized.

(16) An antagonist of claim 15, wherein the lyophilized antagonist is reconstituted with a suitable diluent selected from the group consisting of normal saline, sterile water, glacial acetic acid, sodium acetate and combinations thereof.

(17) A method of developing a nonpeptide GIP antagonist comprising:

using a GIP antagonist to identify characteristics of the GIP antagonist or the antagonist properties of a GIP antagonist; and

developing a nonpeptide GIP antagonist which has characteristics similar to the GIP antagonist or antagonist properties of the GIP antagonist.

5

10

15
20

25

**SPECIFIC ANTAGONISTS FOR GLUCOSE-DEPENDENT
INSULINOTROPIC POLYPEPTIDE (GIP)**

5

Abstract

In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of treating non-insulin dependent diabetes mellitus in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

SEARCHED
SERIALIZED
INDEXED
FILED

Fig. 1A.




Fig. 1B.




Fig. 2.




Fig. 3





Fig. 4.






Fig. 6.




Fig. 7.




Fig. 8.





Fig. 9



Express Mail No. _____

**DECLARATION FOR PATENT APPLICATION AND
POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I (we) believe we are the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

**A SPECIFIC ANTAGONIST FOR GLUCOSE-DEPENDENT
INSULINOTROPIC POLYPEPTIDE (GIP)**

the specification of which

(Check one)

is attached hereto.

was filed on December 3, 1997, as Application Serial No. _____ and

was amended on (if applicable).

I (we) hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I (we) acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I (we) hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):

			<u>Priority Claimed</u>	
<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	<u>Yes</u>	<u>No</u>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

I (we) hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I (we) acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (Patented, Pending, Abandoned)

I (we) hereby appoint the following as our representative(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: PETER J. MANSO (Reg. No. 32,264), A. M. (ANDY) ARISMENDI, JR. (Reg. No. 31,715), JOHN R. KIRK, JR. (Reg. No. 24,477), GERALD T. WELCH (Reg. No. 30,332), C. PATRICK TURLEY (Reg. No. 35,723), LISA H. MEYERHOFF (Reg. No. 36,869), ALAN R. THIELE (Reg. No. 30,694), KEVIN R. HANSBRO (Reg. No. 38,485).

Address all telephone calls to: Peter J. Manso

at telephone No.: (713) 951-3375

Address all correspondence to:
Peter J. Manso, Esquire
JENKENS & GILCHRIST
1445 Ross Avenue, Suite 1800
Dallas, Texas 75202-2799

I (we) hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of inventor M. Michael Wolfe

Inventor's signature _____

Date _____

Residence 31 Montrose Street, Newton, MA 02158

Citizenship _____

Post Office Address 31 Montrose Street, Newton, MA 02158

Full name of inventor Chi-Chuan Tseng

Inventor's signature _____

Date _____

Residence 274 Park Street, Newton, MA 02158

Citizenship _____

Post Office Address 274 Park Street, Newton, MA 02158

Full name of inventor Linda Neville

Inventor's signature _____

Date _____

Residence 10 Draper Avenue, Hull, MA 02158

Citizenship _____

Post Office Address 10 Draper Avenue, Hull, MA 02158

Atty Dkt No 016865-0338
Inventor(s) M. Michael WOLFE, et al
Serial No. 60/032,329
Filed December 3, 1996
Title: A SPECIFIC ANTAGONIST FOR GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP)

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 C.F.R. § 1.9(e) and § 1.27(d)) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION The Trustees of Boston University

ADDRESS OF ORGANIZATION 147 Bay State Road

Boston, Massachusetts 02215

TYPE OF ORGANIZATION

UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
 TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. § 501(a) AND § 501(c)(3))
 NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
 WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. § 501(a) AND § 501(c)(3))
- IF LOCATED IN THE UNITED STATES OF AMERICA
 WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. § 1.9(e) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, with regard to the invention entitled A SPECIFIC ANTAGONIST FOR GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) by inventor(s) M. Michael Wolfe, Chi-Chuan Tseng and Linda Neville

the Specification filed herewith,
 Application No. 60/032,329 filed December 3, 1996
 Patent No. _____ issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each small entity individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor(s), who could not qualify as a small business concern under 37 C.F.R. § 1.9(d) or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 C.F.R. § 1.27).

NAME _____

ADDRESS _____

INDIVIDUAL SMALL BUSINESS CONCERN NONPROFIT ORGANIZATION


I acknowledge the duty to file, in this case, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 C.F.R. § 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Matthew J. Burns

TITLE IN ORGANIZATION Community Technology Fund, Managing Director ad interim

ADDRESS OF PERSON SIGNING Boston University, Boston, MA 02215

SIGNATURE 

ctf

DATE

5/7/98